MedTrace Logo

Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

NCT03149939 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-05-11

No results posted yet for this study

Summary

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Conditions

  • Hyperuricemia
  • Hemodialysis Complication

Interventions

DRUG

Febuxostat 40 milligramsTablet

Febuxostat 40 milligramsTablet every other day for 3 months

Sponsors & Collaborators

  • New Jeddah Clinic Hospital

    collaborator INDUSTRY

  • Benha University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-04-01
Completion
2017-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03149939 on ClinicalTrials.gov